retatrutide phase 2 trial type 2 diabetes weight loss A new weight-loss drug called is generating excitement after clinical participants lost an average of 30% of their body weight, results that rival or even exceed weight-loss surgery. Researchers also Retatrutide, a TRIPLE agonist (GLP1,

Notice the problem with higher doses at this concentration

Pharmacokinetically, retatrutide exhibits a half-life of approximately 6.3 days, enabling once-weekly subcutaneous administration

Lowers Blood Sugar Semaglutide mimics the GLP-1 hormone, which prompts the bodys production of insulin

[2] [3] They also slow gastric emptying, meaning food remains in the stomach longer, contributing to prolonged satiety

while prior centrally-acting drugs posed risks of mood disorders and cardiovascular consequences, the primary adverse effects of GLP-1 receptor agonists are gastrointestinal and often minor or temporary (Zheng et al

If you start on a Friday, Friday becomes your injection day for as long as you take the medication